Publications by authors named "Atsuko Kogure"
Article Synopsis
- A study investigated the link between short sleep duration and the development of non-alcoholic fatty liver disease (NAFLD) among 1,862 Japanese adults who were initially free of the condition.
- Over a median follow-up of 41 months, it was found that 25.9% of participants developed NAFLD, with the highest rates among women sleeping less than 6 hours per night.
- The results indicated that women with short sleep duration had a higher risk of developing NAFLD, suggesting that getting enough sleep may help prevent this condition.
Background And Aim: Equol is a metabolite of soy isoflavone and has estrogenic activity. The incidence of non-alcoholic fatty liver disease (NAFLD) increases after menopause in women, which is thought to result in a decrease in estrogen. This study aimed to evaluate the association between equol and NAFLD.
View Article and Find Full Text PDFThe present study aimed to investigate the incidence of hepatocellular carcinoma (HCC) and factors related to HCC occurrence after direct-acting antiviral (DAA) treatment in the Fukushima Liver Academic Group (FLAG). We conducted a multicenter retrospective cohort study of 1068 patients without cirrhosis (NC) or with compensated liver cirrhosis (LC) who achieved a sustained virologic response (SVR). First, we compared the cumulative HCC incidence and survival rates in NC (n = 880) and LC (n = 188) patients without a history of HCC treatment.
View Article and Find Full Text PDFObjectives: The aim of this study was to assess prevailing treatment of pancreatolithiasis in Japan.
Methods: We surveyed clinical data from 1834 patients (1479 men and 355 women) at 125 hospitals.
Results: Extracorporeal shock-wave lithotripsy (ESWL) was performed alone in 103 patients (5.
Non-alcoholic fatty liver disease (NAFLD) represents one of the most common causes of chronic liver disease worldwide and is characterized by chronic liver inflammation and fibrosis leading to cirrhosis and increased risk of liver cancer in a proportion of patients. Effective anti-fibrotic agents have yet to be approved for the treatment of NAFLD. The present study aimed to evaluate the efficacy of dipeptidyl peptidase 4 inhibitors (DPP4-I) in the prevention of NAFLD progression in NAFLD patients with type 2 diabetes.
View Article and Find Full Text PDF